iBio Supports AzarGen’s Development of a Biosimilar to Rituximab

 iBio Supports AzarGen’s Development of a Biosimilar to Rituximab


  • iBio enters a second statement of work under its MJDA with AzarGen, signed in 2018. The MJDA intends initial contract development and manufacturing of AzarGen’s biosimilars at iBio’s Bryan, Texas facility
  • iBio plans to transfer its FastPharming Manufacturing System to AzarGen in South Africa to produce medicines in the African continent. By leveraging iBio’s FastPharming System, AzarGen will be benefited with the speed, quality and safety of the platform, but also deploy iBio’s support to make newer biologics available at lower costs in Africa
  • In Sept’2019, AzarGen collaborated with iBio to manufacture research quantities of rituximab for bioanalytical testing. Following the completion of initial work, iBio will characterize additional supplies to enable pre-clinical studies comparing plant-made rituximab to the original molecule made using genetically engineered mammalian cells

Click here ­to­ read full press release/ article | Ref: iBio | Image: iBio

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post